Results 161 to 170 of about 5,288 (183)

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. [PDF]

Oncotarget, 2017
Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y, Zhu J.   +11 more
europepmc   +1 more source

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy. [PDF]

Leuk Lymphoma, 2019
Taneja A, Jones J, Pittaluga S, Maric I, Farooqui M, Ahn IE, Wiestner A, Sun C.   +7 more
europepmc   +1 more source

Vascular Endothelial Growth Factors and the Bmx Tyrosine Kinase in the Regulation of Angiogenesis and Lymphangiogenesis [PDF]

, 2003
Paavonen, Karri
core  

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors. [PDF]

Intern Med J
Anderson MA, Awan FT, Berkahn L, Crassini K, Lee HP, Marlton P, Mulligan SP, Nolan M, Tam C, Sverdlov AL.   +9 more
europepmc   +1 more source

In Silico Molecular Docking Analysis of Valproic Acid as an Inhibitor of Bruton's Tyrosine Kinase: Potential Drug Repurposing for Allergies. [PDF]

Cureus
Martinez-Martinez RE, Calva-Hernandez CI, Rodriguez-Lopez GM, Soria-Castro R, Ruiz-Sanchez BP, Chavez-Blanco AD, Pérez-Tapia SM, Pavano-Rodriguez CG, Chacon-Salinas R.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Nature Reviews Clinical Oncology, 2022
Lecia V Sequist, Jessica J Lin
exaly